Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
Novo Nordisk's Ozempic Gets FDA Approval as Kidney-Disease Treatment
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...
FiercePharma4h
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
sicklecellanemianews4h
Companies partner to develop oral treatments for SCD, other diseases
Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo Nordisk announces FDA approval of Ozempic for kidney disease risk
Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...
The Star Worldwide (English) on MSN12h
KMTC, UNHCR announce 50 scholarships for Turkana residents and refugees
The Kenya Medical Training College (KMTC), in partnership with the United Nations High Commission for Refugees (UNHCR), has announced 50 scholarship opportunities for the March 2025 intake. The ...
Le Lézard1d
NVO INVESTOR ALERT: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...
thedailyupside1d
Novo Nordisk May Have Another Blockbuster on its Hands
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.